Sign In
Buy GANX
$1.85
-0.0300 (-1.60%)
At Close: Jun 22, 2026
Gain Therapeutics Earnings Calls
Mar 31, 2026
| Release date | May 11, 2026 |
| EPS estimate | -$0.130 |
| EPS actual | -$0.130 |
| Revenue estimate | 33.333K |
| Revenue actual | - |
Dec 31, 2025
-$0.110 (21.43%)
| Release date | Mar 26, 2026 |
| EPS estimate | -$0.140 |
| EPS actual | -$0.110 |
| EPS Surprise | 21.43% |
| Revenue estimate | 25K |
| Revenue actual | - |
Sep 30, 2025
| Release date | Nov 12, 2025 |
| EPS estimate | -$0.150 |
| EPS actual | -$0.150 |
| Revenue estimate | - |
| Revenue actual | - |
Jun 30, 2025
-$0.190 (-11.76%)
| Release date | Aug 12, 2025 |
| EPS estimate | -$0.170 |
| EPS actual | -$0.190 |
| EPS Surprise | -11.76% |
| Revenue estimate | - |
| Revenue actual | - |
Last 4 Quarters for Gain Therapeutics
Below you can see how GANX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Jun 30, 2025
Missed
| Release date | Aug 12, 2025 |
| Price on release | $1.53 |
| EPS estimate | -$0.170 |
| EPS actual | -$0.190 |
| EPS surprise | -11.76% |
| Date | Price |
|---|---|
| Aug 06, 2025 | $1.55 |
| Aug 07, 2025 | $1.49 |
| Aug 08, 2025 | $1.48 |
| Aug 11, 2025 | $1.46 |
| Aug 12, 2025 | $1.53 |
| Aug 13, 2025 | $1.55 |
| Aug 14, 2025 | $1.54 |
| Aug 15, 2025 | $1.73 |
| Aug 18, 2025 | $1.77 |
| 4 days before | -0.97% |
| 4 days after | 15.69% |
| On release day | 1.31% |
| Change in period | 14.56% |
Sep 30, 2025
| Release date | Nov 12, 2025 |
| Price on release | $2.95 |
| EPS estimate | -$0.150 |
| EPS actual | -$0.150 |
| Date | Price |
|---|---|
| Nov 06, 2025 | $1.90 |
| Nov 07, 2025 | $1.96 |
| Nov 10, 2025 | $2.49 |
| Nov 11, 2025 | $2.68 |
| Nov 12, 2025 | $2.95 |
| Nov 13, 2025 | $2.99 |
| Nov 14, 2025 | $2.83 |
| Nov 17, 2025 | $2.82 |
| Nov 18, 2025 | $2.85 |
| 4 days before | 55.26% |
| 4 days after | -3.39% |
| On release day | 1.36% |
| Change in period | 50.00% |
Dec 31, 2025
Beat
| Release date | Mar 26, 2026 |
| Price on release | $1.89 |
| EPS estimate | -$0.140 |
| EPS actual | -$0.110 |
| EPS surprise | 21.43% |
| Date | Price |
|---|---|
| Mar 20, 2026 | $1.95 |
| Mar 23, 2026 | $1.89 |
| Mar 24, 2026 | $1.86 |
| Mar 25, 2026 | $1.96 |
| Mar 26, 2026 | $1.89 |
| Mar 27, 2026 | $1.83 |
| Mar 30, 2026 | $1.80 |
| Mar 31, 2026 | $1.94 |
| Apr 01, 2026 | $1.94 |
| 4 days before | -3.08% |
| 4 days after | 2.65% |
| On release day | -3.17% |
| Change in period | -0.513% |
Mar 31, 2026
| Release date | May 11, 2026 |
| Price on release | $1.82 |
| EPS estimate | -$0.130 |
| EPS actual | -$0.130 |
| Date | Price |
|---|---|
| May 05, 2026 | $1.87 |
| May 06, 2026 | $1.91 |
| May 07, 2026 | $1.87 |
| May 08, 2026 | $1.82 |
| May 11, 2026 | $1.82 |
| May 12, 2026 | $1.80 |
| May 13, 2026 | $1.78 |
| May 14, 2026 | $1.82 |
| May 15, 2026 | $1.75 |
| 4 days before | -2.67% |
| 4 days after | -3.85% |
| On release day | -1.10% |
| Change in period | -6.42% |
Gain Therapeutics Earnings History
Earnings Calendar
FAQ
When is the earnings report for GANX?
Gain Therapeutics, Inc. (GANX) has scheduled its earnings report for Aug 11, 2026 before the markets open.
What is the GANX price-to-earnings (P/E) ratio?
GANX P/E ratio as of Jun 22, 2026 (TTM) is -3.74.
What is the GANX EPS forecast?
The forecasted EPS (Earnings Per Share) for Gain Therapeutics, Inc. (GANX) for the first fiscal quarter 2026 is -$0.140.
What are Gain Therapeutics, Inc.'s retained earnings?
On its balance sheet, Gain Therapeutics, Inc. reported retained earnings of $0 for the latest quarter ending Mar 31, 2026.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
